Login / Signup

Early Impact of the COVID-19 Pandemic on Acute Stroke Treatment Delays.

Joel Neves BriardCélina DucrouxGrégory JacquinWalid AlesefirWilliam BoisseauNicole DaneaultYan DeschaintreJohanna EnelingLaura C GioiaDana IancuCéline OdierJean RaymondDaniel RoyChristian StapfAlain WeillAlexandre Y Poppe
Published in: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques (2020)
This is an observational cohort study comparing 156 patients evaluated for acute stroke between March 30 and May 31, 2020 at a comprehensive stroke center with 138 patients evaluated during the corresponding time period in 2019. During the pandemic, the proportion of COVID-19 positive patients was low (3%), the time from symptom onset to hospital presentation was significantly longer, and a smaller proportion of patients underwent reperfusion therapy. Among patients directly evaluated at our institution, door-to-needle and door-to-recanalization metrics were significantly longer. Our findings support concerns that the current pandemic may have a negative impact on the management of acute stroke.
Keyphrases
  • end stage renal disease
  • ejection fraction
  • chronic kidney disease
  • newly diagnosed
  • sars cov
  • coronavirus disease
  • prognostic factors
  • bone marrow
  • mesenchymal stem cells
  • combination therapy